4-amino-3-deoxy-N¹⁰-formylpteroic acid | 89043-75-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-amino-3-deoxy-N¹⁰-formylpteroic acid
• 英文别名: 4-amino-4-deoxy-N¹⁰-formylpteroic acid；4-deoxy-4-amino-N¹⁰-formylpteroic acid；4-amino-4-deoxy-(10)N-formylpteroic acid；4-amino-4-deoxy-10-formylpteroic acid；4-amino-4-deoxy-N10-formylpteroic acid；Benzoic acid,4-diaminopteridinyl)-6-methyl] (formyl)amino]-；4-[(2,4-diaminopteridin-6-yl)methyl-formylamino]benzoic acid
• CAS: 89043-75-4
• 化学式: C₁₅H₁₃N₇O₃
• 分子量: 339.313
• InChiKey: SRDZMAPGWAOULQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.4
• 重原子数：
  25
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  161
• 氢给体数：
  3
• 氢受体数：
  9

反应信息

• 作为反应物：
  描述：

  4-amino-3-deoxy-N¹⁰-formylpteroic acid 在 N-甲基吡咯烷酮 、 sodium hydroxide 、 Me₂SiCl 、 三乙胺 、 氯甲酸异丁酯 作用下， 反应 25.75h， 生成 N^α-(4-amino-4-deoxypteroyl)-N^δ-hemiphthaloyl-L-ornithine
  参考文献：
  名称：

  Methotrexate analogs. 33. N.delta.-Acyl-N.alpha.-(4-amino-4-deoxypteroyl)-L-ornithine derivatives. Synthesis and in vitro antitumor activity

  摘要：

  N delta-Acyl derivatives of the potent folylpolyglutamate synthetase (FPGS) inhibitor N alpha-(4-amino-4-deoxypteroyl)-L-ornithine (APA-L-Orn) were synthesized from N alpha-(4-amino-4-deoxy-N10-formylpteroyl)-L-ornithine by reaction with an N-(acyloxy)succinimide or acyl anhydride, followed by deformylation with base. The N delta-hemiphthaloyl derivative was also prepared from 4-amino-4-deoxy-N10-formylpteroic acid by reaction with persilylated N delta-phthaloyl-L-ornithine, followed by simultaneous deformylation and ring opening of the N delta-phthaloyl moiety with base. The products were potent inhibitors of purified dihydrofolate reductase (DHFR) from L1210 murine leukemia cells, with IC50's ranging from 0.027 and 0.052 microM as compared with 0.072 microM for APA-L-Orn. Several of the N delta-acyl-N10-formyl intermediates also proved to be good DHFR inhibitors. One of them, N alpha-(4-amino-4-deoxy-N10-formylpteroyl)-N delta-(4-chlorobenzoyl)-L- ornithine, had a 2-fold lower IC50 than its deformylated product, confirming that the N10-formyl group is well tolerated for DHFR binding. While N delta-acylation of APA-L-Orn did not significantly alter anti-DHFR activity, inhibition of FPGS was dramatically diminished, supporting the view that the basic NH2 on the end of the APA-L-Orn side chain is essential for the activity of this compound against FPGS. N delta-Acylation of APA-L-Orn markedly enhanced toxicity to cultured tumor cells. However, N delta-acyl derivatives also containing an N10-formyl substituent were less cytotoxic than the corresponding N10-unsubstituted analogues even though their anti-DHFR activity was the same, suggesting that N10-formylation may be unfavorable for transport. Two compounds, the N delta-benzoyl and N delta-hemiphthaloyl derivatives of APA-L-Orn, with IC50's against L1210 cells of 0.89 and 0.75 nM, respectively, were more potent than either methotrexate (MTX) or aminopterin (AMT) in this system. These compounds were also more potent than MTX against CEM human lymphoblasts and two human head and neck squamous cell carcinoma cell lines (SCC15, SCC25) in culture. Moreover, in assays against SCC15/R1 and SCC25/R1 sublines with 10-20-fold MTX resistance, the N delta-hemiphthaloyl derivative of APA-L-Orn showed potency exceeding that of MTX itself against the parental cells.(ABSTRACT TRUNCATED AT 400 WORDS)

  DOI：

  10.1021/jm00402a013
• 作为产物：
  描述：

  6-溴乙基-喋啶-2,4-二胺 在 乙酸酐 、 barium(II) oxide 作用下， 以 N,N-二甲基乙酰胺 为溶剂， 反应 26.5h， 生成 4-amino-3-deoxy-N¹⁰-formylpteroic acid
  参考文献：
  名称：

  Methotrexate Analogues. 25. Chemical and Biological Studies on the γ-tert-Butyl Esters of Methotrexate and Aminopterin

  摘要：

  gamma-tert-Butylaminopterin (gamma-tBAMT), the first example of an aminopterin (AMT) gamma-monoester, was synthesized, and new routes to the known N10-methyl analogue gamma-tert-butyl methotrexate (gamma-tBMTX) were developed. The inhibitory effects of gamma-tBAMT on the activity of purified dihydrofolate reductase (DHFR) from L1210 murine leukemia cells, the growth of L1210 cells and CEM human leukemic lymphoblasts in suspension culture, and the growth of several lines of human squamous cell carcinoma of the head and neck in monolayer culture were compared with the effects of gamma-tBMTX and the parent acids AMT and methotrexate (MTX). Patterns of cross-resistance to gamma-tBAMT, gamma-tBMTX, and AMT among several MTX-resistant cell lines were examined. In vivo antitumor activities of gamma-tBAMT and gamma-tBMTX were compared in mice with L1210 leukemia. While the activity of gamma-tBAMT was very close to that of gamma-tBMTX in the DHFR inhibition assay, the AMT ester was more potent than the MTX ester against cells in culture and against L1210 leukemia in vivo. Only partial cross-resistance was shown against gamma-tBMTX and gamma-tBAMT in cultured cells that were resistant to MTX by virtue of a transport defect or a combination of defective transport and elevated DHFR activity.

  DOI：

  10.1021/jm50001a021

文献信息

• Pharmaceutically active ornithine derivatives, ammonium salts thereof and methods of making same
  申请人：——

  公开号：US20040072837A1

  公开（公告）日：2004-04-15

  The present invention relates to pharmaceutically active ornithine compounds, particularly to pharmaceutically acceptable ammonium salts of N &dgr; -acyl derivatives of N &agr; (4-amino-4-deoxypteroyl)-L-omithine compounds; and methods of treatment and pharmaceutical compositions that utilize or comprise one or more of such ammonium salts. The ammonium salts provided by the invention exhibit superior chemical stability than corresponding acidic N &dgr; -acyl derivatives of N &dgr; -acyl derivatives of N &agr; (4-amino-4-deoxypteroyl)-L-ornithine compounds.

  本发明涉及药用活性鸟氨酸化合物，特别是药用可接受的N &dgr; -酰基衍生物的铵盐，以及利用或包含这类铵盐的治疗方法和药物组合物。本发明提供的铵盐比相应的N &dgr; -酰基衍生物表现出更优越的化学稳定性，后者是N &agr; (4-氨基-4-脱氧叶酸)-L-鸟氨酸化合物的酸性N &dgr; -酰基衍生物。
• Methods of treating inflammatory diseases with ammonium salts of ornitihine derivatives
  申请人：Rosenwald A. Lindsay

  公开号：US20050032807A1

  公开（公告）日：2005-02-10

  The present invention relates to pharmaceutically active ornithine compounds, particularly to pharmaceutically acceptable ammonium salts of N δ -acyl derivatives of N α (4-amino-4-deoxypteroyl)-L-ornithine compounds; and methods of treatment and pharmaceutical compositions that utilize or comprise one or more of such ammonium salts. The ammonium salts provided by the invention exhibit superior chemical stability than corresponding acidic N δ -acyl derivatives of N δ -acyl derivatives of N α (4-amino-4-deoxypteroyl)-L-ornithine compounds.

  本发明涉及药用活性鸟氨酸化合物，特别是药用可接受的Nδ-酰基衍生物的Nα(4-氨基-4-脱氧叶酸)-L-鸟氨酸化合物的铵盐；以及利用或包含其中一种或多种这种铵盐的治疗方法和药物组合物。本发明提供的铵盐比相应的Nδ-酰基衍生物的Nδ-酰基衍生物的Nα(4-氨基-4-脱氧叶酸)-L-鸟氨酸化合物表现出更优越的化学稳定性。
• Methotrexate analog. 32. Chain extension, .alpha.-carboxyl deletion, and .gamma. carboxyl replacement by sulfonate and phosphate. Effect on enzyme binding and cell-growth inhibition
  作者：Andre Rosowsky、Ronald A. Forsch、Richard G. Moran、William Kohler、James H. Freisheim

  DOI：10.1021/jm00402a012

  日期：1988.7

  acid side chains in place of glutamate were synthesized and tested as inhibitors of folylpolyglutamate synthetase (FPGS) from mouse liver. The aminophosphonoalkanoic acid analogues were also tested as inhibitors of dihydrofolate reductase (DHFR) from L1210 murine leukemia cells and as inhibitors of the growth of MTX-sensitive (L1210) and MTX-resistant (L1210/R81) cells in culture. The optimal number

  合成了甲氨蝶呤（MTX）和氨基蝶呤（AMT）与氨基膦酸侧链，氨基链烷磺酸和氨基链烷膦酸侧链代替谷氨酸的类似物，并作为小鼠肝脏叶酰聚谷氨酸合成酶（FPGS）的抑制剂进行了测试。还测试了氨基膦酸链烷酸类似物作为L1210鼠白血病细胞中二氢叶酸还原酶（DHFR）的抑制剂，以及培养中MTX敏感（L1210）和MTX耐药（L1210 / R81）细胞生长的抑制剂。发现AMT的氨基膦酰基链烷酸类似物中的CH 2基团的最佳数目对于酶抑制和细胞生长抑制都是两个，但是对于对抗FPGS的活性尤其关键。与先前研究的高半胱氨酸和2-氨基-4-膦酰基丁酸类似物相比，α-羧基的缺失也导致抗-FPGS活性降低。在没有α-羧基的MTX的氨基链烷磺酸类似物中，由于羧酰胺和磺酸酯部分之间的CH2基团数量从一变为四个，因此抗FPGS活性较低，并且变化很小。在类似的MTX氨基烷烃膦酸类似物中，抗FPGS活性也很低，在羧酰胺和膦酸
• [EN] ANTIFOLATE LINKER-DRUGS AND ANTIBODY-DRUG CONJUGATES<br/>[FR] MÉDICAMENTS LIEURS D'ANTIFOLATE ET CONJUGUÉS ANTICORPS-MÉDICAMENT
  申请人：BYONDIS BV

  公开号：WO2022008419A1

  公开（公告）日：2022-01-13

  The present invention relates to novel antifolate linker-drugs, conjugates comprising such antifolate linker-drugs, and the use thereof in the treatment of diseases, such as cancer, autoimmune and infectious diseases, optionally in combination with other therapeutic agents.

  本发明涉及新型抗叶酸连接剂药物，包括这种抗叶酸连接剂的共轭物，并将其用于治疗疾病，如癌症、自身免疫和传染病，可选择性地与其他治疗剂联合使用。
• Methotrexate analogs. 31. Meta and ortho isomers of aminopterin, compounds with a double bond in the side chain, and a novel analog modified at the .alpha.-carbon: chemical and in vitro biological studies
  作者：Andre Rosowsky、Henry Bader、Ronald A. Forsch、Richard G. Moran、James H. Freisheim

  DOI：10.1021/jm00399a013

  日期：1988.4

  Five heretofore undescribed analogues of methotrexate (MTX) and aminopterin (AMT) were synthesized and tested as dihydrofolate reductase (DHFR) inhibitors and tumor cell growth inhibitors. The meta isomer of AMT was obtained from 2,4-diamino-6-(bromomethyl)pteridine and m-(aminobenzoyl)-L-glutamic acid, while the ortho isomer was obtained via the same route by using alpha-methyl gamma-tert-butyl o

  合成了迄今未描述的五个甲氨蝶呤（MTX）和氨基蝶呤（AMT）的类似物，并作为二氢叶酸还原酶（DHFR）抑制剂和肿瘤细胞生长抑制剂进行了测试。AMT的间位异构体是由2,4-二氨基-6-（溴甲基）蝶啶和间-（氨基苯甲酰基）-L-谷氨酸获得的，而邻位异构体是通过相同的途径使用α-甲基γ-叔胺获得的邻-（氨基苯甲酰基）-L-谷氨酸丁酯代替游离酸。由D，L-2-氨基-4-己烯二酸二甲酯和4-氨基-4-脱氧-N10-甲基蝶酸和4-氨基-4-脱氧-甲基二甲基制备在侧链中含有双键的MTX和AMT的类似物。 N10-甲酰基蝶酸。最后，由3- [N-（羧甲基）氨基]丙酸二乙酯和4-氨基-4-脱氧-N10-甲基蝶酸合成MTX的位置异构体，CH2CH2COOH部分从α-碳移至相邻的羧酰胺氮。AMT的位置异构体是弱的DHFR抑制剂，对培养的L1210鼠白血病细胞或耐MTX的L1210 / R81突变株显示很少的生长抑制活性。用CH2CH